Full Press Release Details
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) --Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the BofA Securities 2023 Healthcare Conference in Las Vegas on Wednesday, May 10, 2023 at 11:35 a.m. PT (2:35 p.m. ET).
A live webcast will be available in the Investors & Media section of Dyne’s website athttps://investors.dyne-tx.com/news-and-events/events-and-presentationsand a replay will be accessible for 90 days following the presentation.
About Dyne TherapeuticsDyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD). For more information, please visithttps://www.dyne-tx.com/, and follow us onTwitter,LinkedInandFacebook.